Table 5.
Univariate analysis of the impact of serine/glycine-related protein expression in papillary thyroid carcinoma on disease-free and overall survival by the log-rank test
| Parameter | Number of patientsa/recurrence/death | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
| Mean survival (95 % CI) months | p value | Mean survival (95 % CI) months | p value | ||
| PHGDH in tumor | 0.790 | 0.806 | |||
| Negative | 126/6/6 | 105 (101–108) | 106 (103–109) | ||
| Positive | 218/12/12 | 106 (104–109) | 107 (105–110) | ||
| PSAT1 in tumor | 0.159 | 0.231 | |||
| Negative | 280/17/13 | 106 (103–109) | 108 (106–110) | ||
| Positive | 64/1/5 | 108 (105–111) | 103 (97–108) | ||
| PSPH in tumor | 0.606 | 0.221 | |||
| Negative | 300/15/14 | 107 (105–109) | 108 (106–110) | ||
| Positive | 44/3/4 | 103 (96–110) | 103 (96–109) | ||
| SHMT1 in tumor | 0.498 | 0.248 | |||
| Negative | 236/11/10 | 107 (105–110) | 108 (106–110) | ||
| Positive | 108/7/8 | 104 (100–109) | 105 (101–109) | ||
| SHMT1 in stroma | 0.655 | 0.684 | |||
| Negative | 212/12/10 | 106 (103–109) | 108 (106–110) | ||
| Positive | 132/6/8 | 107 (104–111) | 107 (103–110) | ||
| GLDC in tumor | 0.516 | 0.059 | |||
| Negative | 285/14/12 | 107 (105–109) | 108 (106–110) | ||
| Positive | 59/4/6 | 104 (97–110) | 103 (97–109) | ||
CI confidence interval; PHGDH phosphoglycerate dehydrogenase; PSAT phosphoserine aminotransferase; PSPH phosphoserine phosphatase; SHMT serine hydromethyl transferase; GLDC glycine decarboxylase
aCases of anaplastic carcinoma were excluded